Brief: BriaCell Executes LOI To Advance Clinical Development Of Breast, Prostate Cancer Immunotherapies
07/03/2024 15:39
March 7 (Reuters) - Briacell Therapeutics Corp BCT.TO :
* BRIACELL RECEIVES AND EXECUTES LETTER OF INTENT TO ADVANCE
CLINICAL DEVELOPMENT OF BREAST AND PROSTATE CANCER
IMMUNOTHERAPIES
Source text for Eikon: ID:nGNX8q43Ft
Further company coverage: BCT.TO
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Briacell Therapeutics
See all newsBrief: Briacell Therapeutics Prices 1.45 Million Common Shares At $3.25 Per Share
Brief: Briacell Receives Positive Recommendation From Data Safety Monitoring Board (Dsmb) For Phase 3 Study In Metastatic Breast Cancer
Brief: Briacell Expands Pipeline To Include An Ovarian Cancer Immunotherapy Candidate, Bria-Ova+™
Brief: Briacell Phase 3 Bria-Imt™ Study Enrollment Surpasses 230 Patients
Brief: Briacell Adds Nyu Langone Health’S Perlmutter Cancer Center As Clinical Site In Pivotal Phase 3 Breast Cancer Study